A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO): NRG-BR008

Authors

• Lior Braunstein
• Melissa Mitchell
• Hanna Bandos
• William Sikov
• Atif Khan
• Peter Chen, Corewell Health East
• Patricia Ganz
• Reshma Jagsi
• Julia White
• Reena Cecchini
• Hyejoo Kang
• Shannon Puhalla
• Kelly Bolton
• Eileen Connolly
• Erica Stringer-Reasor
• Kimberly Gergelis
• Thomas Julian
• Eleftherios M
• Norman Wolmoark

Document Type

Conference Proceeding - Restricted Access

Publication Date

7-2025

Publication Title

Annals of Surgical Oncology

Volume

32

Issue

2 Suppl

First Page

S441

Last Page

S442

Recommended Citation

Braunstein L, Mitchell M, Bandos H, Sikov W, Khan A, Chen P, et al. A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008. Ann Surg Oncol. 2025 Jul;32(2 Suppl):S441-S442. doi:10.1245/s10434-025-17646-6

Comments

26th Annual Meeting of the American Society of Breast Surgeons (ASBrS), April 30 - May 4, 2025, Las Vegas, NV

DOI

10.1245/s10434-025-17646-6